UCB to Sell U.S. Generic Unit to Advent, Avista Capital

Updated on

UCB SA agreed to sell its U.S. generic-drug unit to Advent International and Avista Capital Partners for $1.53 billion, causing the stock to dip as the company pushed back a profitability goal.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.